Latest Period
Q1 2026
Security Snapshot
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) Institutional Ownership
CUSIP: 501575104
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
253
Shares (Excl. Options)
96,284,588
Price
$83.29
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- KYMR on Nasdaq
- Shares outstanding
- 81,496,373
- Price per share
- $88.07
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 96,284,588
- Total reported value
- $8,013,051,308
- % of total 13F portfolios
- 0.01%
- Share change
- +6,195,235
- Value change
- +$522,615,210
- Number of holders
- 253
- Price from insider filings
- $88.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- KYMR - Kymera Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 501575104.
- 253 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 253 to 253 between Q4 2025 and Q1 2026.
- Reported value moved from $6,991,150,975 to $8,013,051,308.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 253 institutions filings for Q1 2026.
Security key
501575104
Latest holder period
Q1 2026
13F holders
253
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
KYMR full holder history
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Kymera Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501575104:
Significant Owners of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +28% | $1,034,158,808 | +$243,712,112 | 11,681,450 | +31% | FMR LLC | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP | 11% | +14% | $551,236,913 | +$127,711,627 | 8,676,797 | +30% | Baker Bros. Advisors LP | 09 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.5% | $436,311,906 | 6,867,809 | BVF PARTNERS L P/IL | 11 Dec 2025 | |||
| T. Rowe Price Investment Management, Inc. | 6.7% | $483,396,552 | 5,460,257 | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.1% | $288,530,046 | 5,097,704 | T. Rowe Price Associates, Inc. | 30 Sep 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | -12% | $344,353,990 | -$46,322,968 | 3,889,687 | -12% | Wellington Management Group LLP | 31 Mar 2026 |
| BlackRock, Inc. | 5.4% | $165,983,856 | 3,803,227 | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 253 institutional investors reported holding 96,284,588 shares of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR). This represents 118% of the company’s total 81,496,373 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) together control 100% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 11,699,950 | +31% | 0.05% | $974,488,873 |
| BAKER BROS. ADVISORS LP | 11% | 8,657,242 | 0% | 4.1% | $721,061,686 |
| Avoro Capital Advisors LLC | 9.2% | 7,474,747 | 0% | 6.1% | $622,571,678 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7.4% | 6,060,847 | -1.6% | 0.06% | $504,809,000 |
| BVF INC/IL | 6.8% | 5,502,710 | 0% | 15% | $458,320,716 |
| T. Rowe Price Investment Management, Inc. | 6.7% | 5,464,997 | +768% | 0.31% | $455,180,000 |
| BlackRock, Inc. | 6.2% | 5,060,876 | +1.1% | 0.01% | $421,520,382 |
| Atlas Venture Life Science Advisors, LLC | 5.6% | 4,578,008 | -1.8% | 48% | $381,302,286 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | 3,889,687 | -12% | 0.06% | $323,972,031 |
| Siren, L.L.C. | 3.9% | 3,186,830 | -3% | 7.4% | $265,431,071 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,880,324 | 0% | 0.01% | $239,902,186 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.5% | 2,874,056 | 0% | 0.01% | $239,380,124 |
| STATE STREET CORP | 2.9% | 2,389,767 | +8.1% | 0.01% | $199,043,693 |
| Capital Research Global Investors | 2.1% | 1,673,275 | +7.2% | 0.02% | $139,367,075 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,645,350 | +16% | 0.01% | $137,066,393 |
| Driehaus Capital Management LLC | 1.3% | 1,043,583 | -2.4% | 0.64% | $86,920,028 |
| UBS Group AG | 1.3% | 1,023,852 | +39% | 0.02% | $85,276,632 |
| GOLDMAN SACHS GROUP INC | 1.1% | 888,409 | +20% | 0.01% | $73,995,585 |
| ALLIANCEBERNSTEIN L.P. | 1.1% | 888,035 | -6.7% | 0.02% | $69,098,003 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.1% | 875,872 | -4% | 0.02% | $72,951,379 |
| Holocene Advisors, LP | 1% | 836,759 | +9.9% | 0.17% | $69,693,657 |
| Merck & Co., Inc. | 0.95% | 772,165 | 0% | 18% | $64,313,623 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 0.93% | 759,848 | +19% | 0.65% | $63,287,740 |
| Commodore Capital LP | 0.92% | 750,000 | 0% | 3.6% | $62,467,500 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.77% | 626,925 | +0.08% | 0.86% | $52,213,101 |
Institutional Holders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 96,284,588 | $8,013,051,308 | +$522,615,210 | $83.29 | 253 |
| 2025 Q4 | 89,844,612 | $6,991,150,975 | +$715,972,868 | $77.81 | 253 |
| 2025 Q3 | 80,864,737 | $4,576,806,879 | +$137,276,130 | $56.60 | 207 |
| 2025 Q2 | 78,801,021 | $3,438,754,240 | +$270,821,262 | $43.64 | 208 |
| 2025 Q1 | 72,808,716 | $1,995,263,098 | +$5,348,226 | $27.37 | 171 |
| 2024 Q4 | 71,721,890 | $2,885,022,540 | +$14,409,751 | $40.23 | 177 |
| 2024 Q3 | 69,051,239 | $3,268,392,680 | +$183,360 | $47.33 | 174 |
| 2024 Q2 | 67,390,465 | $2,011,640,213 | +$5,551,590 | $29.85 | 153 |
| 2024 Q1 | 67,207,302 | $2,701,742,064 | +$296,832,171 | $40.20 | 161 |
| 2023 Q4 | 60,455,852 | $1,539,280,108 | +$89,020,891 | $25.46 | 134 |
| 2023 Q3 | 57,350,132 | $797,188,696 | -$18,249,775 | $13.90 | 120 |
| 2023 Q2 | 58,230,116 | $1,338,678,295 | +$29,100,921 | $22.99 | 124 |
| 2023 Q1 | 56,859,649 | $1,683,467,091 | +$23,131,891 | $29.63 | 123 |
| 2022 Q4 | 56,195,243 | $1,402,708,961 | +$98,529,765 | $24.96 | 116 |
| 2022 Q3 | 52,859,306 | $1,150,805,258 | +$29,150,428 | $21.77 | 119 |
| 2022 Q2 | 49,442,050 | $973,574,555 | +$16,502,218 | $19.69 | 99 |
| 2022 Q1 | 45,688,568 | $1,933,296,396 | +$62,437,636 | $42.32 | 124 |
| 2021 Q4 | 43,015,870 | $2,729,867,438 | +$128,644,677 | $63.49 | 123 |
| 2021 Q3 | 34,637,185 | $2,035,073,191 | +$491,859,746 | $58.74 | 115 |
| 2021 Q2 | 26,479,657 | $1,284,263,574 | +$188,105,374 | $48.50 | 109 |
| 2021 Q1 | 22,191,421 | $862,345,865 | +$92,686,286 | $38.86 | 94 |
| 2020 Q4 | 20,299,967 | $1,247,002,136 | +$53,009,741 | $62.00 | 74 |
| 2020 Q3 | 16,828,031 | $542,529,000 | +$542,529,000 | $32.31 | 51 |